https://www.gov.uk/government/news/mhra-approves-guselkumab-for-crohns-disease-and-ulcerative-colitis#:~:text=The%20Medicines%20and%20Healthcare%20products,plaque%20psoriasis%20and%20psoriatic%20arthritis.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 May 2025, approved guselkumab (Tremfya) to treat Crohn's disease and ulcerative colitis (UC).

Guselkumab is currently approved to treat plaque psoriasis and psoriatic arthritis. However, clinical studies have shown that guselkumab is also efficacious in treating adults with moderately to severely active Crohn's disease and UC who have not responded well to other treatments or experienced unacceptable side effects.

Using guselkumab in Crohn's disease can benefit patients by reducing the signs and symptoms of the disease, which can include diarrhoea and abdominal pain. In UC it helps to reduce abdominal pain and inflammation of the intestinal lining. These effects can improve a patient's ability to do normal daily activities and reduce fatigue.

Guselkumab can be administered either by intravenous infusion or injection for the initial treatment of Crohn's disease. For UC, initial treatment will be administered via an intravenous infusion.